Isolation and characterization of exosome-enriched urinary extracellular vesicles from Dent's disease type 1 Spanish patients
Objective To evaluate the clinical utility of the Baveno classification in predicting incident cardiovascular mortality after five years of follow-up in a clinic-based cohort of patients with obstructive sleep apnea (OSA). Materials and Methods We evaluated the reproducibility of the Baveno classifi...
| Autores: | , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2023 |
| País: | España |
| Recursos: | Universitat de Lleida (UdL) |
| Repositório: | Repositori Obert UdL |
| OAI Identifier: | oai:repositori.udl.cat:10459.1/465679 |
| Acesso em linha: | https://doi.org/10.1016/j.nefroe.2024.01.016 https://hdl.handle.net/10459.1/465679 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Obstructive sleep apnea Cardiovascular Hypoxia Latino Precision medicine Enfermedad de Dent Exosomas Vesículas extracelulares DD1 CLCN5 |
| Resumo: | Objective To evaluate the clinical utility of the Baveno classification in predicting incident cardiovascular mortality after five years of follow-up in a clinic-based cohort of patients with obstructive sleep apnea (OSA). Materials and Methods We evaluated the reproducibility of the Baveno classification using data from the Santiago Obstructive Sleep Apnea (SantOSA) study. The groups were labeled Baveno A (minor symptoms and comorbidities), B (severe symptoms and minor comorbidities), C (minor symptoms and severe comorbidities), and D (severe symptoms and comorbidities). Within-group comparisons were performed using analysis of variance (ANOVA) and post hoc tests. The associations between groups and incident cardiovascular mortality were determined through the Mantel-Cox and Cox proportional hazard ratios (HRs) adjusted by covariables. Results A total of 1,300 OSA patients were included (Baveno A: 27.7%; B: 28%; C: 16.8%; and D: 27.5%). The follow-up was of 5.4 years. Compared to Baveno A, the fullyadjusted risk of cardiovascular mortality with Baveno B presented an HR of 1.38 (95% confidence interval [95%CI]: 0.14–13.5; p¼0.78); with Baveno C, it was of 1.71 (95%CI: 0.18–16.2; p¼0.63); and, with Baveno D, of 1.04 (95%CI: 0.12–9.2; p¼0.98). We found no interactions involving Baveno group, sex and OSA severity. Discussion Among OSA patients, the Baveno classification can describe different subgroups. However, its utility in identifying incident cardiovascular mortality is unclear. Long-term follow-up studies and the inclusion of demographic variables in the classification could improve its ability to detect a high-risk phenotype associated with cardiovascular mortality. Conclusion The Baveno classification serves as a valuable method for categorizing varying groups of patients afflicted with OSA. Nevertheless, its precision in identifying occurrence of cardiovascular mortality is still unclear. |
|---|